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ABSTRACT
In the late B cell differentiation stages, miRNAs expression modifications 
promoting or inhibiting key pathways are only partially defined. We isolated 29 CD19+ 
human B cell samples at different stages of differentiation: B cells from peripheral 
blood; naïve, germinal center (GC) and subepithelial (SE) B cells from tonsils. SE cells 
were further split in activated and resting B cell. The miRNA expression profile of these 
B cells was assessed by microarray analysis and selected miRNAs were validated by 
quantitative RT-PCR and in situ hybridization on normal tonsils. The comparison of 
all samples showed changes in 107 miRNAs in total. Among 48 miRNAs differentially 
expressed in naïve, GC and SE cells, we identified 8 miRNAs: mir-323, mir-138, mir-9*, 
mir-211, mir-149, mir-373, mir-135a and mir-184, strictly specific to follicular cells 
that had never been implicated before in late stages of B cell development. Moreover, 
we unveiled 34 miRNAs able to discriminate between CD5− activated B cells and 
resting B cells. The miRNAs profile of CD5− resting B cells showed a higher similarity 
to naïve CD5+ than CD5− activated B cells. Finally, network analysis on shortest paths 
connecting gene targets suggested ZEB1 and TP53 as key miRNA targets during the 
follicular differentiation pathway. These data confirm and extend our knowledge on 
the miRNAs-related regulatory pathways involved in the late B cell maturation.
INTRODUCTION
Newly formed immature B cells, that express an 
unrefined antigen receptor, are released from the bone 
marrow to blood circulation and they conclude their 
differentiation in the follicles of peripheral lymphoid 
organs [1]. In the immune follicles, a combination of death 
and survival stimuli results in T-cell dependent selection of 
functionally mature IgV class-switched and hypermutated 
antibody-producing B lymphocytes [2]. Ontogenesis of 
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B cells is accomplished under the concerted action of 
multiple factors performing transcriptional programs 
entailing down- or up- modulation of genes at each 
stage of maturation [3, 4]. In this scenario, MicroRNAs 
(miRNAs) play their own part as well [5].
MiRNAs are non-protein coding RNAs active in the 
regulation of gene transcription and mRNA translation. 
MiRNAs action in concert with transcriptional inhibitors 
and enhancers results in the fine tuning of gene expression. 
As a consequence, miRNAs influence many cellular 
processes, such as cell identity, growth, proliferation and 
control of cell death [6].
Multiple evidences indicated a critical role of specific 
miRNAs in B cell development [7–9]. In the follicles, 
during late maturation stages, the down-regulation 
of mir-150, which controls the transcription factor c-Myb, 
is requested for the germinal centre (GC) selection and for 
a correct development of the adaptive humoral immune 
response [10]. Other miRNAs such as mir-155, mir-181b, 
mir-15a, mir-16, mir-15b, mir-34a, mir-9, mir-30, let-7a, 
mir-125b, mir-217 and mir-185 modulate the expression 
of pivotal genes and functions which contribute to the final 
B-cell maturation [6]. Also the couple mir-150/c-Myb is 
involved in the B cell lineage differentiation pathway [11]. 
The GC is a transient structure that forms within 
peripheral lymphoid organs in response to B lymphocyte 
stimulation by T cell-dependent antigens, with the 
involvement of other immune cells. Up- and down-regulation 
of multiple miRNAs was detected in B cells at sequential 
stages of maturation during the GC reaction [12–14]. Some 
of the miRNAs highlighted by profiling studies were then 
demonstrated to be functionally relevant [11]. Thus, it 
appears crucial to identify selective miRNAs that influence 
and drive B cell development to better characterize the 
molecular pathways involved in this biological process.
The marginal zone B cells population is 
heterogeneous, comprising naïve and memory cells 
[15, 16]. The subepithelial region of tonsils, corresponding 
to the marginal zone of other peripheral lymphoid organs, 
on the basis of the pattern of surface markers, contains 
two subpopulations of supposedly mature CD5− B cells: 
resting and activated [17]. Activated B cells are IgV gene-
hypermutated B cells that achieved the final maturation. 
Instead, similarly to mice, human SE resting B cells could 
represent a subpopulation of IgV gene-unmutated B cells 
survived to the GC selection and waiting for activation by 
a specific antigene to complete their maturation process 
[18, 19]. As the miRNAs expression pattern characterizes 
different B cell maturation stages, it could also contribute 
to define the ontogenesis of these two B cell subsets.
In this study, we compared the expression profiles of 
miRNAs in CD19+ B cells at different late differentiation 
steps by microarray analysis. In addition, we compared the 
expression profile of miRNAs in subepithelial activated 
and resting B cells, to better define the identity of the two 
B cell subtypes. Experimentally validated gene targets 
of differentially expressed miRNAs were subjected to 
network analysis, to infer the underlying regulatory 
pathways. By this procedure, we tried to identify protein 
hubs and cell functions operated by miRNAs.
RESULTS
One hundred and seven single miRNAs were 
significantly differentially expressed in CD19+ B 
cells from blood compared to B cells from tonsils 
at different stages of activation
We assessed miRNAs expression in B cell subsets 
representing stages of development ranging from 
CD19+ peripheral blood B cells to mature B cells in the 
immune follicles of tonsils. We analyzed a total of 29 
B cell samples by microarray technology: four samples 
of CD19+ B cells isolated from peripheral blood; 14 
B cell samples isolated from tonsil follicles, that were 
divided in three different groups: naïve CD5+ B cells (2 
samples), CD23−CD39− GC B cells (12 samples) and 
CD5− SE mature B cells (11 samples). Finally, among 
the 11 samples of mature CD5− B cells, we defined two 
distinctive subgroups: the IgV-hypermutated activated B 
cells (4 samples) and the IgV-non-hypermutated resting 
B-cells (seven samples). On summary, on the basis of 
the differentiation stage, our B cell samples could be 
divided in four different experimental groups, including 
the subepithelial CD5− B cells which are subdivided in 
two subgroups.
The heat map in Supplementary Figure 1 shows the 
levels of differentially expressed miRNAs among four B-cell 
subsets. The hierarchical clustering emphasized the correlation 
among samples belonging to the same differentiation stage 
(Supplementary Figure 1A). One hundred and seven single 
miRNAs were differentially expressed among the five B-cell 
subsets at FDR 1% (Supplementary Figure 1B). The list of 
135 probes representing 107 single miRNAs is reported in 
Supplementary Table 1.
Most of miRNA expression differences occurred 
between CD19+ and naïve CD5+ cells. Among follicular 
B cell populations, CD23−CD39− GC B-cells showed an 
expression profile well distinct from that of naïve CD5+ B 
cells and mature CD5− B cells. Indeed, these latter two cell 
populations showed only a limited number of differentially 
expressed miRNAs. Therefore, this analysis highlighted 
the strong modulation of miRNA expression during the 
late B cell differentiation.
The expression of thirty-seven single miRNAs 
distinguishes peripheral blood CD19+ from 
CD19+/CD5+ B cells of lymph node
About 70% of peripheral blood CD19+ cells are 
immature or naïve CD19+/CD5−/+ B lymphocytes before 
joining peripheral lymphoid compartments for the 
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achievement of the antigen-dependent final maturation as 
high affinity antibody secreting plasma cells [20]. When 
these immature B cells reach the microenvironment of the 
white zone of the immune follicles, they become CD5+ B 
cells. To identify miRNAs involved in this B cell transition, 
we compared the miRNA profile of CD19+ B cells isolated 
from blood to the miRNA profile of CD5+ B cells isolated 
from tonsils: the expression levels of 37 miRNAs appeared 
changed in a statistically significant manner (FDR 5%). 
Among these differently expressed miRNAs, 22 were 
downregulated, whilst, on the contrary, 15 miRNAs 
were upregulated in CD5+ B cells compared to CD19+ B 
cells (Supplementary Figure 2, Supplementary Table 2). 
Downregulated miRNAs in CD5+ cells included members 
of both the mir-29 and mir-30 families as well as the 
mir-17-92 cluster. On the contrary, we identified, among 
the upregulated miRNAs, members of the mir-132 and 
mir-212 families, that generated a specific cluster on 
chromosome 17.
Modulation of miRNAs expression allows the 
clusterization of naïve, GC and mature SE B 
cells samples
To identify miRNAs that are actively modulated 
during the GC maturation, we compared the expression 
profiles of miRNAs obtained from three main follicular 
B cell populations: naïve B cells (CD5+), GC B cells 
(CD23−CD39−) and mature SE B cells (CD5−). Statistical 
procedures clustered three homogeneous groups of samples 
(Figure 1A). Moreover, CD5− B cell samples were split 
in the two different clusters of activated and resting. 
Forty-eight single miRNAs, corresponding to 61 spots, were 
significantly differentially expressed among the 25 samples 
(at FDR 1%) and they were clusterized in three main groups: 
cluster 1, composed by 28 miRNAs; cluster 2, composed 
by 8 miRNAs; and cluster 3 composed by 12 miRNAs 
(Figure 1B). Cluster 1 included miRNAs whose expression 
increased in the passage from naïve B cells to GC B-cells 
and activated CD5− B cells. Moreover, miR-323, mir-138 
and miR-204 were more highly expressed in naïve and 
SE B cells. Cluster 2 comprised miRNAs downregulated 
in GC B cells compared to naïve and CD5− activated B 
cells. Finally, cluster 3 included miRNAs whose expression 
decreased during the transition from CD5+ to CD23−CD39− 
and activated CD5− B cells (Figure 2). Considering all 
differentially expressed miRNAs, we detected miR-150, 
miR-361, miR-130b, miR-181b and members of miRNA 
clusters miR-17-5p, miR-106a, miR-20a and miR-20b as the 
most variable miRNAs (FDR = 0.0077) (Table 1).
MiRNAs belonging to the cluster mir-17/92 and the 
paralogous clusters mir-25/106b and mir-106a/363 showed 
a similar trend of expression, i.e. mir-17-5p, mir-20a, 
mir-106a, mir-20b, mir-18a, mir-106a, mir-18b, mir-20b, 
mir-106b, mir-93 and mir-25 (Cluster 1, Figure 1). The 
same expression pattern was also present in the cluster of 
mir-191/425, (Cluster 1, Figure 1).
The average expression levels of the top 20 
significantly differentially expressed miRNAs (Figure 2) 
demonstrated that they were mostly upregulated in mature 
B cells. In contrast, miR-150, miR-361, miR-221, miR-135a, 
miR-141, miR-185 and miR-149 decreased in GC B cells 
compared to naïve B cells.
Finally, naïve CD5+ B-cells shared with activated 
CD5− B-cells a specific group of miRNAs whose 
expression resulted downregulated in CD23−CD39− 
B-cells (Figure 1). In addition, among miRNAs expressed 
at higher level in CD5− B cells compared to CD5+ B cells, 
we identified five miRNAs: miR-29a, miR-29b, miR-29c, 
miR-26a and miR-221. The expression level of these 
miRNAs was comparable to those of CD23−CD39− B cells. 
Therefore, we can conclude that the B cell maturation 
step allowing the entrance in peripheral lymphoid organs 
induces the upregulation of a restricted group of miRNAs: 
miR-29a, miR-29b, miR-29c, miR-26a and miR-221.
To better reinforce our original data, by comparing 
our results with published data we generated a list of 48 
differentially expressed miRNAs [12–14] (Table 2). The 
four studies considered for the comparison, including the 
present study, demonstrated the higher expression in naïve 
B-cells of mir-320, the up-regulation of mir-181b, mir-25, 
miR-130b in GC B cells as well as the greater expression 
of both mir-29a and seven members linked to the cluster 
miR-17/92 in mature B cells. Moreover, in at least one 
of the four studies, 35 of 48 differentially expressed 
miRNAs were expressed at higher level in different 
B cell subsets; on the contrary, 27 miRNAs were not 
differentially expressed or not detected. However the four 
studies presented a controversial expression of mir-185: 
we detected levels of miR-185 higher in naïve than in GC-
restricted B cells (Figure 1), whilst both Malumbres et al. 
[12] and Belver et al. [21] showed miR-185 upregulation 
in GC B cells.
Our study identified 8 new differentially expressed 
miRNAs: mir-323, mir-138, mir-9*, mir-211, mir-149, 
mir-373, mir-135a and mir-184; that have not been 
reported in literature so far.
Expression of thirty-three selective miRNAs 
discriminates subepithelial resting and marginal 
zone CD5− activated B-cells
As described by Dono M et al., 2000 [17], resting 
CD5− B cells were identified in the SE region of tonsils 
as small size CD5− B cells expressing unmutated IgV 
genes. The ontogenesis of this cell population has not been 
defined yet, as well as the difference between resting and 
activated B cells, generated from B cells of GCs adjacent 
to SE. Therefore, we proceeded to analyze the miRNAs 
profiles of these two B cell subtypes, comparing four 
samples of CD5− activated B cells to seven samples of 
CD5− resting B cells (Figure 3). The two cell populations 
clustered separately and they are strongly distinguishable 
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for the differential expression of 34 miRNAs (FDR 5%). 
The miRNAs profile comparison between resting and 
activated B cells showed the up-regulation of 19 miRNA 
in activated B cells: mir-98, mir-106a, mir-20a, mir-17-5p, 
mir-20b, mir-16-2, mir-18a, mir-155, mir-21, mir-181d, 
mir-425-5p, mir-148a, mir-15b, mir-15a, mir-181b mir-
181c, mir-181a, mir-130b, mir-148b (Table 3). Conversely, 
15 miRNAs resulted downregulated in activated B cells: 
mir-483, mir-95, mir-326, mir-135a, mir-184, mir-185, 
mir-516-3p, mir-30b, mir-203, mir-216, mir-150, mir-
182*, mir-141 and mir-211 (Table 3).
Validation of miRNAs expression by quantitative 
RT-PCR
We validated our microrray results by quantitative 
RT-PCR on CD5+, GC and CD5− activated and resting B cell 
mRNA samples as shown in Supplementary Figure 3. In 
fact, we validated 10 different miRNAs: mir-150, mir-20b, 
mir-23a, mir-211, mir-15b, mir-21, mir-106a, mir-146a, 
mir-9* and mir-155 whose expression trends by 
quantitative RT-PCR highlighted the same expression 
trend shown by microarray analysis. The only discrepancy 
between RT-PCR and microarray analysis data was 
referred to miR-23a expression: this miRNA, in fact, did 
not show a significantly differential expression among the 
four B cell subsets by microarray analysis but it did show 
a significant upregulation by RT-PCR (P = 0.002) in CD5− 
activated B cells compared to the other B cell subsets. 
Statistical analysis of quantitative RT-PCR results using 
Kruskal-Wallis test confirmed the differential expression 
of these miRNAs among the B cells subsets analyzed 
(Supplementary Figure 3).
Validation of miR-9*, miR-29b and miR-150 on 
normal tonsils by in situ hybridization 
We validated by in situ hybridization miR-9*, 
miR-29b and miR-150, selected from microrray results. 
The analysis was conducted in five pharyngeal tonsils 
Figure 1: Expression profile of miRNAs in cell subsets representing different stages of B cell maturation. CD5+: naïve 
B cells from tonsils; CD23−CD39−: germinal centre (GC) B cells from tonsils; CD5−: subepithelial (SE) mature B cells from tonsils, 
subdivided in CD5− resting and CD5− activated B cells. (A) Array tree of 25 samples representing different stages of maturation of the 
B cells based on the expression levels of miRNAs. (B) The heat map describes the expression levels of 48 differentially expressed miRNAs 
in 25 samples owning to four B cell subsets isolated from tonsils (FDR 1%). Clusters 1, 2 and 3 are three miRNAs groups isolated by 
clustering procedures. Red, higher expression (log
2
, +4); green, lower expression (log
2
, −4).
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using mature miRNA labeled probes (Figure 4). The 
expression of the three miRNAs was detectable as a 
grainy blue cytoplasmic staining. MiR-9* was significantly 
overexpressed in germinal centers (GC), mantle zone 
(MZ), and subepithelial marginal zone (MaZ) in 
comparison to squamous epithelium (Sq). At higher 
magnification, it is evident a stronger expression in GC 
cells in comparison to MZ. MiR-29b was significantly 
overexpressed in both MZ and MaZ in comparison to 
GC. MiR-150 was significantly downregulated in GC in 
comparison to both MZ and MaZ.
Identification of genes regulated by differentially 
expressed miRNAs in the late B cell development
Using the differentially expressed miRNA profiles, 
we generated a list of 608 experimentally validated gene 
targets (Supplementary Table 3), that were filtered through 
the gene ontology category “lymphocyte differentiation” 
(GO:0030098). The distribution of 28 miRNA targets 
generated by the three clusters of differentially expressed 
miRNAs is shown in Figure 5A, where the Venn diagram 
highlighted two shared selective gene targets among 
the three miRNA clusters: ZEB1 and TP53 genes. In 
particular, we identified two selective miRNA lists: the 
first one, composed by miR-150, miR-130b, miR-141, 
miR-29b, miR-26a, miR-34a and miR-200c, able to target 
the ZEB1 gene; and the second one, composed by miR-
150, miR-221, miR-21 and miR-25, able to target the TP53 
gene. The only common miRNA between the two lists is 
miR-150.
Finally, we compared the expression levels of seven 
ZEB1- and four TP53-targeting miRNAs in naïve and GC 
B cells (Figure 5B): all ZEB1-targeting miRNAs were 
expressed at higher level in naïve compared to GC B 
cells; while only three (miR-221, miR-21 and miR-25) out 
Figure 2: Expression levels of top 30 differentially expressed miRNAs in cell subsets representing different stages of 
late B cell differentiation. Graphs report expression levels of 30 miRNAs with lower Q value among the 48 differentially expressed 
miRNAs in 29 samples divided in four B cell subsets. Color graphs indicate the miRNAs included in Cluster 1 (yellow), Cluster 2 (orange) 
and Cluster 3 (green). Data were obtained from microrray analysis after normalization and log
2
 transformation of the probe signal. 0: naïve 
B cells; 1: germinal centre B cells; 2: subepithelial activated B cells; 3: subepithelial resting B cells.
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Table 1: List of differentially expressed miRNAs among CD5+ B cells, CD23−/CD39− B cells and 
CD5− B cells (FDR 2%)
miRNA Q value
miR-150 0.0077
miR-17-5p 0.0077
miR-106a 0.0077
miR-20a 0.0077
miR-181b 0.0077
miR-361 0.0077
miR-130b 0.0077
miR-20b 0.0077
miR-18a 0.0081
miR-29b 0.0082
miR-148a 0.0082
miR-191 0.0083
miR-93 0.0086
miR-26a 0.0086
miR-221 0.0086
miR-155 0.0087
mir-15b 0.0087
miR-29a 0.0087
miR-138 0.0098
miR-106b 0.0102
miR-135a 0.0102
miR-21 0.0102
mir-16-2 0.0102
miR-181c 0.0102
miR-141 0.0102
mir-185 0.0102
miR-149 0.0106
miR-181d 0.0110
miR-425-5p 0.0110
miR-29c 0.0110
miR-181a 0.0110
miR-25 0.0124
mir-204 0.0136
mir-184 0.0136
miR-148b 0.0136
miR-373 0.0138
miR-9* 0.0138
mir-30b 0.0138
miR-19b 0.0147
mir-320 0.0153
miR-146a 0.0153
miR-30a-3p 0.0156
miR-9 0.0156
mir-323 0.0159
mir-211 0.0159
miR-328 0.0164
mir-335 0.0178
miR-15a 0.0198
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Table 2: B cell subsets with highest level of miRNAs significantly modulated during the late 
differention of B cells: a comparison with literature data
miRNA Malpeli G et al. Zhang J et al. Malubres S et al. Tan LP et al.
miR-323 GC ND ND ND
miR-138 GC ND ND ND
miR-204 GC GC ND ND
miR-181b GC GC GC GC
miR-25 GC GC GC GC
miR-9* GC ND ND ND
miR-16-2 GC ND GC GC
miR-15a GC GC ND ND
miR-15b GC GC GC ND
miR-425-5p GC ND ND GC
miR-148a GC Mat GC GC
miR-148b GC ND GC Naïve
miR-155 GC ND GC ND
miR-146a GC GC-Mat Mat ND
miR-19b GC GC GC GC
miR-130b GC GC GC GC
miR-93 GC GC GC GC
miR-106b GC GC GC GC
miR-18a GC GC GC GC
miR-17-5p GC GC GC GC
miR-20b GC GC GC GC
miR-106a GC GC GC GC
miR-20a GC GC GC GC
miR-181a GC ND GC GC
miR-181c GC ND Naïve-GC ND
miR-181d GC GC Naïve-GC ND
miR-191 GC ND GC GC
miR-21 Mem Mem GC Mem
miR-30a-3p Mem GC GC ND
miR-361 Mem Mem ND GC
miR-29c Mem Mem-Naïve GC Mem
miR-29b Mem ND GC Mem-Naïve
miR-29a Mem Mem-Naïve Mem Mem
miR-26a Mem Naïve Naïve Mem
miR-221 Mem Mem Naïve Naïve-Mem
miR-150 Naïve ND Mem Naïve
miR-9 Naïve GC ND ND
miR-30b Naïve GC Mem GC
miR-141 Naïve Naïve ND ND
miR-211 Naïve ND ND ND
miR-149 Naïve ND ND ND
miR-373 Naïve ND ND ND
miR-135a Naïve ND ND ND
miR-320 Naïve Naïve-Mem Naïve-Mem Naïve-Mem
miR-335 Naïve Naïve ND ND
miR-185 Naïve ND GC ND
miR-184 Naïve ND ND ND
miR-328 Naïve ND GC-Mem ND
ND: not detected or not differentially expressed; Naïve: naïve B cells; GC: germinal centre B cells; Mat: mature B cells. Zhang 
J et al. [14], Malubres S et al. [12], Tan LP et al. [13].
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of four TP53- targeting miRNAs (except miR-150) were 
upregulated in GC B cells.
Network analysis based on the experimentally 
validated gene targets of differentially expressed 
miRNA
To discover the selective cellular pathways 
targeted by the identified miRNAs, we performed a 
network analysis To infer proteins and cellular pathways 
modulated by miRNAs, we consulted a global intracellular 
protein-protein interactome (http://dp.univr.it/~laudanna/
LCTST/downloads/index.html). For each cluster of 
differentially expressed miRNAs, we identified the nodes 
involved in the shortest paths among experimentally 
validated miRNA targets listed in Figure 5A. We 
considered the proteins with highest degree (hubs) as the 
most perturbed targets by the biological processes under 
investigation. Finally we generated for each miRNA 
cluster a sub-network including only the hubs and the 
Figure 3: Differential expression of miRNAs in subepithelial CD5− activated and resting B cell subsets. The heat map 
reports the expression levels of differentially expressed miRNAs between two subepithelial (SE) CD5− B cell populations (FDR 10%): 
activated IgV mutated SE B cells and resting IgV unmutated SE B cells. Red, higher expression (log
2
, +4); green, lower expression (log
2
, −4).
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paths that are connected to the differentially expressed 
miRNAs. Using this representation, we highlighted 
the relationship between miRNA-related changes and 
potential protein targets. We identified a cluster 1-related 
sub-network that was composed by 133 items, including 
the 5 main hubs (APC, ATM, CTNNB1, ERBB2, TP53); 
a cluster 2-related sub-network that contained 30 items, 
including the 6 hubs (GRB2, HDAC4, HSP90AA1, 
PIK3R1, TP53 and ZEB1) and, finally, a cluster 3-related 
sub-network that included 9 hubs (APC, BCL6, ELAVL1, 
HDAC1, HDAC2, HSP90AA1, SOCS5, SUMO1 and 
ZEB1) (Figure 6A–6C respectively).
Gene ontology analysis
To better define the miRNA-related regulatory 
potential functions on controlling B cell biological 
modifications during the GC reaction, we analyzed 
Table 3: List of differentially expressed miRNAs between subepithelial CD5− activated and resting 
B cells (FDR 10%)
miRNA *activated vs resting Q value
mir-211 Down 0.0026
miR-148a Up 0.0340
mir-141 Down 0.0445
miR-155 Up 0.0445
mir-184 Down 0.0445
miR-15b Up 0.0445
mir-30b Down 0.0445
miR-150 Down 0.0445
miR-148b Up 0.0445
mir-16-2 Up 0.0445
miR-216 Down 0.0445
mir-185 Down 0.0445
miR-18a Up 0.0445
miR-17-5p Up 0.0448
miR-130b Up 0.0448
miR-516-3p Down 0.0448
miR-106a Up 0.0500
miR-21 Up 0.0500
miR-95 Down 0.0551
miR-20b Up 0.0833
miR-425-5p Up 0.0833
miR-181b Up 0.0833
miR-181a Up 0.0833
miR-135a Down 0.0833
miR-181c Up 0.0853
mir-203 Down 0.0855
miR-15a Up 0.0855
miR-483 Down 0.0855
miR-182* Down 0.0855
miR-20a Up 0.0855
miR-181d Up 0.0909
miR-98 Up 0.0911
mir-326 Down 0.0986
*Up: higher expression in activated CD5− B cell.
Down: higher expression in resting CD5− B cell.
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the gene annotation of all primary protein-interactors 
connected to the shortest paths analyses. We identified 
52 Panther pathways and 49 Panther hallmarks that 
were significantly over-represented as reported in 
Supplementary Table 4 and Supplementary Table 5, 
respectively. The top 10 enriched cellular pathways were: 
“CCKR signaling map“ (P = 1.66 × 10−64); “Gonadotropin 
releasing hormone receptor pathway“ (P = 1.44 × 10−41); 
“Angiogenesis“ (P = 7.15 × 10−39); “EGF receptor 
signaling pathway“ (P = 7.92 × 10−36); “Apoptosis 
signaling pathway“ (P = 5.86 × 10−35); “Interleukin 
signaling pathway“ (P = 6.91 × 10−35); “B cell activation” 
(P = 1.73 × 10−32); “T cell activation“ (P = 1.14 × 10−30); 
“Inflammation mediated by chemokine and cytokine 
signaling pathway” (P = 8.44 × 10−28); “Integrin signalling 
pathway“ (P = 1.04 × 10−27) (Supplementary Table 4). 
The top 10 enriched hallmarks categories were: 
“Genes up-regulated during transplant rejection” 
(P = 7.09 × 10−57); “Genes up-regulated by activation 
of the PI3K/AKT/mTOR pathway” (P = 7.47 × 10−46); 
“Genes involved in the G2/M checkpoint, as in progression 
through the cell division cycle“ (P = 7.91 × 10−46); “Genes 
important for mitotic spindle assembly“ (P = 1.66 × 10−43); 
“A subcluster of genes regulated by MYC - version 1 (v1)” 
(P = 12.14 × 10−42); “Genes encoding cell cycle related 
targets of E2F transcription factors“ (P = 1.85 × 10−35); 
“Genes mediating programmed cell death (apoptosis) 
by activation of caspases“ (P = 3.82 × 10−31); “Genes 
regulated by NF-kB in response to TNF [GeneID = 7124]”; 
(P = 3.87 × 10−31); “Genes involved in p53 pathways and 
networks“ (P = 4.87 × 10−29); “Genes up-regulated in 
response to IFNG [GeneID = 3458]” (P = 5,00 × 10−28) 
(Supplementary Table 5). 
DISCUSSION
MiRNAs establish regulatory networks by 
intersecting and affecting multiple signaling pathways 
[22, 23]. Trying to disclose the miRNA-related regulatory 
actions during the late phase of B cell differentiation, 
we firstly identified miRNAs profiles of B cell subsets 
in different maturative phases and their prospective 
relationships in association to the cell machinery. Using 
this strategy, we identified molecular pathways that are 
modulated by selective miRNAs.
Microarray or quantitative RT-PCR analyses 
have already assessed the miRNAs involved in the late 
differentiation of B cells [12–14]. The results reported in 
literature, however, are partially conflicting about both 
the number of differentially expressed miRNAs and 
their expression levels. In this complex scenario our data 
achieved some essential goals that can be summarized in 
the following points: 1) the cell transition from immature 
to mature B lymphocytes is strictly characterized by the 
modulation of 107 miRNAs: 33 miRNAs change their 
expression during B cell passage from blood to peripheral 
lymphoid organs; 2) the three main B cell populations in 
tonsils (naïve, GC and SE B cells) involved in the GC 
Figure 4: MiR-9*, miR-29b and miR-150 distribution in normal tonsillar tissue. The expression of the three miRNAs was 
detectable in pharyngeal tonsils as a grainy blue cytoplasmic staining. MiR-9* was significantly overexpressed in germinal centers (GC), 
mantle zone (MZ), and subepithelial marginal zone (MaZ) in comparison to squamous epithelium (Sq). At higher magnification, it is evident 
a stronger expression in GC cells in comparison to MZ. MiR-29b was significantly overexpressed in both MZ and MaZ in comparison to 
GC, whereas miR-150 was significantly downregulated in GC in comparison to MZ and MaZ. Bar scale = 200 µm.
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reaction showed distinct expression profiles: 48 miRNAs 
are differentially expressed during the GC reaction 
and they are segregated in three clusters according 
to the sequential maturative stages; 3) among the 48 
differentially expressed miRNAs, we identified 8 new 
original miRNAs (mir-323, mir-138, mir-9*, mir-211, 
mir-149, mir-373, mir-135a and mir-184) that were not 
previously reported as discriminative miRNAs during B 
cell development; 4) the expression of 34 miRNAs are able 
to discriminate between resting and activated CD5− SE 
B cells; moreover, miRNAs from resting CD5− B cell 
better resemble miRNAs from naïve B cell rather than 
miRNAs from activated CD5− B cell ; 5) during the late 
phase of B cell differentiation ZEB1 and TP53 are the 
most influenced targets by the differentially expressed 
miRNAs; 6) APC, ATM, CTNNB1, ERBB2, TP53, BCL6, 
SOCS5, HDAC4, HDAC2, HDAC1, GRB2, PIK3R1, 
HSP90AA1, ZEB1, SUMO1 and ELAVL1 are the main hub 
proteins that are controlled by the identified miRNAs; 7) 
gene ontology analysis showed that miRNAs controls core 
signaling pathways and essential for B cell functions.
Moreover, our new identified differentially 
expressed miRNAs are related to other specific aspects of 
B cell biology. We discovered that miR-323 expression was 
reduced in activated mature B cells compared to naïve and 
GC B cells. This miRNA was reported as a biomarker of 
immune and inflammatory response, since it is an activator 
of the Wnt/Cadherin signaling pathway and it induces 
cytokine expression and tissue metalloproteases [24] in 
rheumathoid arthritis. Moreover, miR-323 was recently 
described to target EED, a component of the polycomb 
repressive complex 2 (PRC2) [25], that plays an essential 
role in GC formation; in fact, the modulation of miR-323 
in the follicles was reported as a critical and relevant event 
Figure 5: (A) Distribution 28 genes targeted by differentially expressed miRNAs in the three clusters reported in Figure 1. Venn diagram 
reports the distribution and intersection of target genes of differentially expressed miRNAs which belong to the gene ontology category 
“lymphocyte differentiation”. Two boxes indicate the miRNAs known to target ZEB1 and TP53. (B) Differential expression of miRNAs 
known to target ZEB1 and TP53 between naïve and GC B cells.
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of the adaptive immune response [26]. Recently, mir-138 
was shown to target acyl protein thioesterases (LYPLA1 
and LYPLA2) able to regulate the palmitoylation of CD95 
and apoptosis in chronic lymphoblastic leukemia [27]. 
Mir-138 was found upregulated in follicular lymphoma 
but downregulated in the GC subtype of diffuse large B 
cell lymphoma [28] [29]. The over-expression of mir-211 
has been already associated with lymphoma progression 
[30]. By contrast, specific alterations of Mir-9* expression 
were never reported in normal B cell populations, even if 
this miRNA is a selective marker of follicular lymphomas 
[28]. Similarly, the differential expression levels of 
mir-149 were never described during physiological B 
cell development even if its downregulation have been 
associated to both diffuse large and follicular lymphoma 
[28, 31]. Finally, the differential expression of mir-373 
was reported in several neoplastic diseases except in 
lymphomas [32]; on the contrary, both the mir-135a 
downregulation (able to target JAK2) and miR-135a 
overexpression were associated to relapse of Hodgkin’s 
[33] and follicular and diffuse large B cell lymphomas 
[29, 31]. Finally, the downregulation of mir-184 was 
reported in marginal zone lymphoma [34]. 
A very interesting observation is related to miR-185 
expression pattern: published results, in fact, demonstrated 
that this miRNA was upregulated in mouse GC B cells 
and downregulated in human GC B cells after stimulation 
of naïve B cells with lipopolysaccharide antigen 
[21, 35]. MiR-185 is able to switch off the BTK kinase, 
that plays a critical role in controlling the positive and 
negative selection of autoreactive B cells in mice [36], 
by influencing the B cell receptor signaling pathway 
[21]. Our data confirmed that miR-185 is downregulated 
in human GC B cells. In fact, based on these evidences, 
we speculate that miR-185 level, in connection with other 
regulatory mechanisms having different weights in human 
and mice, participates to the fine tuning of the threshold 
for the selection of autoreactive B cells.
Figure 6: Network of proteins obtained by shortest path analysis among target genes of miRNA differentially expressed 
(Figure 1), their first interactor proteins and miRNAs targeting hub proteins and first interactors. Dark grey square: hub 
proteins, that is proteins nodes of the network with higher degree; light grey circle: protein first interactors of hub proteins; white hexagon: 
miRNA targeting hub proteins. In tables, list of hub proteins (bold letters), first interactors of hub proteins and miRNAs targeting hub 
proteins and their first interactors present in the network. (A) Network of target proteins of miRNA listed in Cluster 1 of Figure 1, their first 
interactor proteins and miRNAs targeting hub proteins and first interactors. (B) Same representation as in 6A by using the miRNAs listed 
in Cluster 2 of Figure 1. (C) Same representation as in 6A by using the miRNAs listed in Cluster 3 of Figure 1. 
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The SE niche of tonsils is populated by mature 
CD5− B cells comprising small resting B lymphocytes 
and activated plasmablasts with peculiar phenotypic 
characteristics [37, 38]. According to the classical 
view of the primary immune response, the non-cycling 
hypermutated class-switched mature B cells are the 
progeny of adjacent positively antigen-selected GC B 
cells [17, 39]. Instead, the nature of SE resting cells not-
class switched, IgV gene unmutated and insensitive to T 
helper-mediated activation, remains elusive [17, 40, 41]. 
In mice, the memory pool contains stable fractions of 
unmutated and mutated IgV gene cells [19]. In humans, 
the memory B cell compartment is not totally well defined 
and the existence of a T helper- and GC-independent 
pathway of maturation of B cells is still controversial [41]. 
According to our data, activated and resting mature B cells 
have unique expression profiles of miRNAs. These data 
reinforced the hypothesis that these two B cell populations 
are truly two distinct entities: in fact, the miRNA profile 
of resting CD5− B cells better resembled that of naive 
CD5+ B cells rather than that of activated CD5− B cells. In 
addition, the SE resting cells showed the upregulation of 
a set of miRNAs tipically upregulated in activated mature 
B cells compared to GC B cells. Therefore, our results 
clearly demonstrated that resting CD5− B cells could be 
defined as a specific subpopulation of CD5+ B cells that 
have exceed the GC selection and partially acquired the 
features of mature B cells.
In the GC reaction, the balance between positive and 
negative inputs is critical for an effective physiological 
response to antigens [42]. We identified the ZEB1 and 
TP53 genes as main targets of differentially expressed 
miRNAs during the late B cell differentiation. ZEB1–
targeting miRNAs are downregulated on GC B cells, 
suggesting a possible biological effect on B cells promoted 
by the increased ZEB1 expression level. ZEB1 is involved 
both in cell reprogramming and in the epithelial-to-
mesenchymal transition; but its role in B cell development 
is still unclear. In mice, Zeb1 expression is required for 
GC formation and memory B cell response. The enforced 
Zeb1 expression after the B cell receptor (BCR)-antigen 
binding promoted both proliferation and altered apoptotic 
death of naïve B cells [43]. Moreover, Zeb1 plays a critical 
role in regulating the functions of BCL6 that is a rheostat 
factor in controlling B cell fate. In fact, ZEB1 binds the 
E-box motif that controls the BCL6 and SMAD genes 
regulating the GC reaction and the TGF-β1 signaling 
pathway, respectively [44]. In humans, Zeb1 is almost 
absent in quiescent B cells of the mantle zone but it is 
expressed in proliferating GC B cells of tonsils (http://
www.proteinatlas.org/ENSG00000148516-ZEB1/tissue/
tonsil). High Zeb1 expression was also associated with 
adverse overall survival in diffuse large and mantle B 
cell lymphomas [45–47]. The higher Zeb1 expression 
levels in malignant lymphomas suggest its involvement 
during B cell differentiation either at early stages or after 
BCR activation. Therefore, all these evidences indicate 
that miRNAs could contribute to set Zeb1 levels and 
action timing during early cellular events following BCR 
activation.
TP53 exerts a central role in maintaining cell 
homeostasis following genotoxic insults. BCL6 modulates 
the B cell response inducing tolerance to DNA damage-
induced apoptosis by suppressing TP53 in GC B cells, 
[48]; while P53 controls the cell cycle at two distinctive 
checkpoints (G1/S and G2/M) by the regulation of 
miR-107, miR-145, miR-34, and of the miRNA clusters 
miR-15a/miR-16 and miR-192/miR-194/miR-215, able to 
target many cell cycle-related genes [49]. An increased 
level of TP53-targeting miRNAs in GC B cells such 
as miR-21, miR-25 and miR-200c could promote an 
additional control level of TP53 expression after the 
activation of the DNA damage response. 
By expanding our analysis through the protein 
interactome, we identified hub proteins under the 
control of modulated miRNAs during the late B cell 
differentiation. These target proteins are involved in 
different pathways suggesting that these miRNAs can 
regulate several signaling networks that are activated 
during B cell development. We identified some hub 
proteins that have been already reported as key player 
in main signaling pathways, but also some specific 
hubs that were recently directly implicated in the B cell 
development. In particular, we identified ELAVL1 (also 
known as HuR), that plays an essential role in the GC 
reaction and class-switched antibodies production [50]. 
We demonstrated that miR-9, which targets ELAVL1, 
decreased its expression in the transition from naïve to GC 
and mature B cells, suggesting that miRNA could control 
HuR expression levels.
In conclusion, we described the modulation of 
miRNAs and the involvement of underlying miRNA 
targets and cellular functions in the late B cell maturation. 
Our findings complement the results reported in previous 
studies and offer new hints for further functional studies 
addressing the comprehension of the role played by 
miRNAs in B lymphocyte biology.
MATERIALS AND METHODS
Samples
Twenty-nine CD19+ normal B cell samples were 
studied. Four CD19+ B cell samples were obtained from 
the peripheral blood of four healty donors and twenty-
five CD19+ normal B cell samples were prepared from 
nonpathological tonsils after surgical removal at the 
National Institute for Cancer Research of Genova. The 
materials used have been collected under Program 1-IC01 
protocol IC/01/LLC/001 13/12/2001, renewed 28/11/2013. 
The protocols, which concerned the collection of the 
informed consent of patients, were approved by the local 
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ethics committee of the IRCCS Azienda Ospedaliera 
Integrata San Martino – IST Istituto Nazionale per la 
Ricerca sul Cancro (Genova). Among B cell samples 
from tonsils, two were naïve CD5+ B cells (each sample 
was a pool of five different donors), twelve samples 
were CD23−CD39− GC B cells; eleven samples were 
CD5− subepithelial mature B cells. Among the eleven SE 
CD5− B cell samples, four samples were SE CD5− IgV 
hypermutated activated B cells and seven samples were SE 
CD5− not IgV hypermutated resting B cells. Subepithelial 
CD5− B cells of tonsils are equivalent to the marginal zone 
B cells in other peripheral lymphoid organs [17]. 
Cell separations and RNA extraction
Pure populations of B lymphocytes were isolated by 
antibody-conjugated magnetic beads sorting according to 
established protocols. CD19+ cells were isolated from the 
peripheral blood of healthy donors by positive selection 
with anti-CD19 antibody magnetic beads-conjugated 
and magnetic sorting. Four CD19+ B cell populations, 
naïve B cells (CD5+), GC B cells (CD23−CD39−) and 
two populations of CD5− B cells, SE activated IgD+ (IgV 
gene mutated) and SE resting IgD− (IgV gene unmutated), 
were isolated from tonsils as previously described [17]. 
Purity of B lymphocytes was at least 95%, according to 
cytofluorometer analysis. Total RNA was isolated from 
cells using TRIZOL reagent (Invitrogen) according to 
manufacturer protocol. RNA concentration and integrity 
was determined respectively by spectrophotometer and 
agarose gel separation
Microarrays 
MicroRNA labeling and hybridization were 
performed using 5 mgmicrograms total RNA, as described 
[51]. We used a multi-species microarray platform 
containing 2284 probes, 1256 for human and 1028 for 
mouse targets, respectively. A total of 353 human mature 
or pre-miRNA were detectable by the microarray. Each 
human target was matched by at least two probes, with an 
average of 4.3 probes for each target. Hybridization signals 
were detected with Streptavidin-Alexa647 conjugate and 
scanned images (Axon 4000B) were quantified using the 
Genepix 6.0 software (Axon Instruments).
Data analysis 
Expression data from microarrays were normalized 
and transformed using the vsn package for R. The spots 
were subsequently classified based on their target sequence 
regardless of the original designation. The expression 
measures for probes matching the same miR sequence 
were summarized using the medpolish algorithm, in 
order to obtain a unique expression figure for each target. 
Clustering analysis was performed using the hclust function 
and the inverse Pearson correlation as a distance metric, 
for both genes and arrays. All the clusters were visualized 
using the Java TreeView software (http://jtreeview.
sourceforge.net). To select differentially expressed genes, 
we performed either anova or t-tests. To take into account 
multiple hypothesis testing, the FDR (false discovery rate) 
was calculated using the qvalue package for R. All the 
genes with a FDR less than 0.01 were used in subsequent 
analyses. All the calculations were performed using the R 
statistical software (http://www.r-project.org).
Evaluation of miRNAs expression by 
quantitative RT-PCR
For each sample and for each miRNA, 5 ng of total 
RNA was converted to cDNA by TaqMan MicroRNA 
Reverse Transcription kit (Applied Biosystems) with the 
miRNA specific primer contained in the TaqMan MicroRNA 
assays (Applied Biosystems). MiRNA expression was 
evaluated in 10 µL total volume by quantitative RT-PCR 
following the manufacturer protocol in the presence of 1× 
TaqMan Universal Master Mix (Applied Biosystems) on a 
7900HT SDS instrument (Applied Biosystems). Expression 
differences of miRNAs among samples were determined 
by the comparative method according to User Bulletin #2 
(Applied Biosystems) using the noncoding RNA RNU44 
and RNU6B as reference gene.
MiRNA in situ hybridization analysis
Locked nucleic acid (LNA) probes with 
complementarity to miR-9*, miR-29b, and miR-150 were 
labelled with 5′-biotin and synthesised using Exiqon 
(Vedbaek, Denmark). Tissue sections were digested 
with ISH protease 1 (Ventana Medical Systems, Milan, 
Italy) and ISH was performed as we previously described 
(PMID:27618837). Positive (U6; Exiqon) and negative 
scrambled LNA probes (Exiqon) were used as controls. 
Only cytoplasmic miRNA staining was retained for 
scoring purposes.
Network analysis 
Experimentally validated target genes (only target 
genes marked as “strong evidence”) of differentially 
expressed miRNAs were retrieved from MirTarBase 4.5 
database [52]. Among the predicted targets, only those 
included in the GO category “lymphocyte differentiation” 
(GO:0030098) were kept. Using the filtered targets and a 
database of protein interactions (http://dp.univr.it/~laudanna/
LCTST/downloads/index.html), comprising 14642 proteins 
and 270062 edges, we generated subnetworks which 
included the shortest paths joining the primary targets. 
Shortest paths were calculated with PeSca application 3.0 
version implemented in Cytoscape 3.0 [53].
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Gene ontology and pathway analysis
A comprehensive list of first interactors of genes 
which are nodes of the shortest paths was submitted 
to Panther (Protein ANalysis THrough Evolutionary 
Relationships) Classification System at http://pantherdb.
org/) for evaluation of enrichment of annotations for 
functional classification and cellular pathways [54, 55]. 
For gene ontology and pathway analysis, a significant 
value threshold of 0.05 was applied.
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